All In Biotech

Free tool

FAERS Monitor: Tresiba

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 203314 or its brand name (Tresiba, Insulin Degludec). Reports on generic versions are filed under their own applications.

Reports

23,942

Serious

14,201

59% of reports

Hospitalization

7,060

Death reported

1,331

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased3,805
  • nausea1,536
  • blood glucose decreased1,309
  • drug ineffective1,059
  • off label use1,059
  • vomiting1,028
  • diarrhoea982
  • hypoglycaemia981
  • fatigue923
  • dyspnoea835
  • constipation733
  • fall726
  • dizziness702
  • headache678
  • abdominal pain611

Reports by year received

View as table
YearReports
20111
20135
201454
2015121
20161,013
20172,063
20182,346
20192,124
20202,450
20212,426
20222,114
20231,928
20242,359
20253,106
20261,832

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,030,217 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood glucose decreasedSignal1,30924.623.328,859
hypoglycaemiaSignal98118.117.015,560
blood glucose increasedSignal3,80518.117.660,706
constipationSignal7333.02.8956
abdominal painSignal6112.32.1457
vomiting1,0281.91.8464
fall7261.91.8323
nausea1,5361.71.6465
diarrhoea9821.31.386
dyspnoea8351.31.258
dizziness7021.21.132
off label use1,0591.11.04
fatigue9231.01.02
headache6780.90.92
drug ineffective1,0590.70.7138

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.